Combined Therapy Lowers Potassium Faster in Trial
A randomized trial found that pairing nebulized salbutamol with insulin-dextrose reduced serum potassium more than either drug alone in acute hyperkalemia.
Updated on Nov. 16, 2026 in Diabetes

Results from the INSAKA randomized controlled trial, presented at ASN Kidney Week in Denver from October 21-25, 2026, showed that combining nebulized salbutamol with insulin-dextrose lowered serum potassium more than either treatment given separately. The study randomly assigned 410 adults with serum potassium of 5.5 mmol/L or higher, and 398 patients were included in the analyses.
Why it matters
Hyperkalemia can be dangerous, and clinicians often need fast-acting options when potassium levels are elevated. The findings suggest a combined approach may produce a larger biochemical effect, though whether that difference improves patient outcomes has not yet been tested.
The trial enrolled 410 adults with a median age of 76 years, one-third of whom were women, and reported a combination-therapy potassium reduction of 1.3 mmol/L at 60 minutes. Hyperglycemia was less frequent with salbutamol monotherapy, and other adverse event rates did not differ meaningfully among the arms.
The players
ASN Kidney Week
The annual kidney health conference hosted by the American Society of Nephrology, where researchers present major clinical and scientific findings in nephrology.
The details
Patients were randomly assigned to intravenous insulin-dextrose (10 units), nebulized salbutamol (10 mg), or both drugs at the same dosages, with study drugs administered over 30 minutes. The primary endpoint was the change in serum potassium from baseline to 60 minutes, measured against a median baseline of 6.2 mmol/L.
Timeline
October 21-25, 2026: INSAKA trial results presented at ASN Kidney Week in Denver, Colorado.
Clinical Context
The INSAKA trial tests acute potassium-lowering strategies used in emergency hyperkalemia management, a setting where clinicians have historically relied on insulin-dextrose and beta-agonists given separately. Its head-to-head comparison of these agents, alone and combined, offers a direct test of whether pairing them adds measurable benefit beyond either drug alone.
For patients with high potassium, the findings point toward a possible faster-acting combined treatment, but current practice should follow clinician guidance until outcome data are available. Patients with kidney disease or those taking potassium-raising medications should discuss potassium monitoring with their care team.
The takeaway
A combined approach lowered potassium more than either drug alone in this trial, but whether that faster drop protects patients remains an open question for future research.
Further reading
For broader background on blood sugar and insulin-related treatments, explore our Diabetes coverage.
Source note: This article includes information reported by Renal and Urology News.



